Kioxia’s AI Project Wins 2020 Field Innovation Award Silver Prize From Japanese Society for Artificial Intelligence
22.6.2021 11:57:00 EEST | Business Wire | Press release
Kioxia Corporation, a world leader in memory solutions, announced today that it was awarded the 2020 Field Innovation Award Silver Prize by the Japanese Society for Artificial Intelligence (JSAI) for its TEZUKA 2020 project. TEZUKA 2020 brought AI and humans together in collaboration to create a new manga, or comic book, in the nearly identical artistic style of manga legend Osamu Tezuka.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210622005554/en/
Plot development (Graphic: Business Wire)
The Field Innovation Award recognizes individuals and organizations that leverage AI technology to solve real-life issues and advance the state of business and society.
The TEZUKA 2020 project was acclaimed as an innovative use of AI technology to develop a new manga, which involves combining numerous elements of storytelling, including location settings, characters, plot development, dialogues, panel layouts and speech bubbles. Through the AI technology, the project team created prototypes for new plots and characters, all while honoring the unique and highly recognizable Tezuka style. Human artists then used these AI-created prototypes to develop a complete, full-length manga entitled “PHAEDO.”
Kioxia, guided by its mission of uplifting the world with memory, uses AI technology to support creativity as well as to improve production efficiency and quality through memory solutions.
The members of the TEZUKA 2020 project are as follow:
- Hitoshi Matsubara, Professor at the University of Tokyo
- Satoshi Kurihara, Professor at Keio University
- Kazushi Mukaiyama, Professor at Future University Hakodate
- Yoji Kawano, Assistant Professor at Keio University
- Atsushi Nakajima, Digital Transformation Technology R&D Center, Kioxia Corporation
- Atsushi Kunimatsu, SSD Division, Kioxia Corporation
- Masato Ishiwata, Director of Creative Division, Tezuka Productions
- Makoto Tezuka, Director at Tezuka Productions
- Daisuke Tsutsui, Director of Brand & Innovation Division, Wunderman Thompson Tokyo
- Ryohei Orihara, Digital Transformation Technology R&D Center, Kioxia Corporation
Creating plots with AI
To enable AI to learn the essence of Tezuka’s works and artistry, 130 of his creations were deconstructed and split into 13 common plot development phases to be used as data. The AI technology used that data to generate story outlines (Figure 1), generating over 100 plots in total. Thereafter, the project members discussed the storyline options, some of which had highly unexpected twists that people would not likely have imagined, and ultimately selected the plot that became the basis of “PHAEDO.”
Creating characters with AI
This project used an AI technology called Generative Adversarial Networks (GAN), which learned Tezuka’s authentic artistry to generate characters that were extremely close to his style. Some 4,500 facial images were gathered, but only a small number of the images were ideally suited to machine learning due to their orientation and proportions (Figure 2). To enable the AI to learn the characteristics of Tezuka’s illustrated human faces, the project team introduced a process called “transfer learning” to the AI technology, allowing it to accurately learn Tezuka’s manga characters and generate its own characters in his unique style (Figure 3).
About Kioxia
Kioxia is a world leader in memory solutions, dedicated to the development, production and sale of flash memory and solid-state drives (SSDs). In April 2017, its predecessor Toshiba Memory was spun off from Toshiba Corporation, the company that invented NAND flash memory in 1987. Kioxia is committed to uplifting the world with memory by offering products, services and systems that create choice for customers and memory-based value for society. Kioxia's innovative 3D flash memory technology, BiCS FLASH™, is shaping the future of storage in high-density applications, including advanced smartphones, PCs, SSDs, automotive and data centers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210622005554/en/
Contact information
Kota Yamaji
Public Relations
Kioxia Holdings Corporation
81-3-6478-2319
kioxia-hd-pr@kioxia.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
